Beam Therapeutics SVP granted 40,000 stock options

Beam Therapeutics Inc. granted a stock option to senior executive Bethany J. Cavanagh, SVP, Finance and Treasurer.

Accepted by SEC EDGAR 02/02/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Beam Therapeutics Inc. granted a stock option to senior executive Bethany J. Cavanagh, SVP, Finance and Treasurer. On 01/31/2026, she received a stock option to buy 40,000 shares of Common Stock at an exercise price of $27.62 per share, expiring 01/31/2036.

The option was awarded for no cash consideration and is held directly. It vests in equal monthly installments over the 48 months following the grant date, conditioned on her continued service with Beam Therapeutics Inc. through each vesting date.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Cavanagh Bethany J

Role SVP, Finance and Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 40,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Beam Therapeutics (BEAM) disclose in this Form 4 filing?

Beam Therapeutics reported a stock option grant to Bethany J. Cavanagh, its SVP, Finance and Treasurer. She received options for 40,000 shares of Common Stock on January 31, 2026, as part of her compensation, subject to a long-term vesting schedule and continued service.

How many Beam Therapeutics shares are covered by Bethany Cavanagh’s new stock option?

The stock option granted to Bethany Cavanagh covers 40,000 shares of Beam Therapeutics Common Stock. These options are held directly and represent her total beneficial ownership of derivative securities following the reported transaction on January 31, 2026, according to the filing’s transaction table.

What is the exercise price and expiration date of the Beam Therapeutics options granted?

The granted stock option has an exercise price of $27.62 per share and expires on January 31, 2036. This gives the executive the right to buy Beam Therapeutics Common Stock at that fixed price any time before expiration, subject to the vesting conditions being satisfied.

How do Bethany Cavanagh’s Beam Therapeutics options vest over time?

The options vest in equal monthly installments over 48 months following the January 31, 2026 grant date. Vesting is contingent on Bethany Cavanagh’s continued service with Beam Therapeutics Inc. through each monthly vesting date, aligning the award with ongoing employment and long-term commitment.

Did Bethany Cavanagh pay anything for the Beam Therapeutics stock option grant?

The Form 4 shows a price of $0 for the stock option itself, indicating it was granted as compensation rather than purchased. However, exercising the option later would require paying the $27.62 per-share exercise price to acquire Beam Therapeutics Common Stock.

What role does Bethany Cavanagh hold at Beam Therapeutics related to this Form 4?

Bethany J. Cavanagh is identified as an officer of Beam Therapeutics, serving as Senior Vice President, Finance and Treasurer. The Form 4 reflects an equity compensation grant to her in that capacity, documenting her derivative beneficial ownership in compliance with Section 16 reporting rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cavanagh Bethany J

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.62	01/31/2026		A		40,000		(1)	01/31/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.